diagnostics
Tests that detect and monitor disease: lab instruments, test kits and molecular and genetic testing.
Industry · 7 companies · 5 report it as a revenue line
ABT Abbott Laboratories
Sells it 25%, $3.3B a quarter“Diagnostics rose 46.7% in Q3 (46.6% excluding FX); 9M sales were $8.577B versus $6.480B, up 32.4% reported and 30.8% excluding FX.”
- Revenue$13.0BYoY +14.5%
- Net income$920.0MYoY −44.0%
- Revenue$2.2BYoY +17.3%
- Net income$426.3MYoY +14.8%
BRKR Bruker
Sells it, part of BSI CALID“Develops, manufactures, and distributes innovative solutions for microbial identification, antibiotic resistance and susceptibility testing, polymerase chain reaction (“PCR”) based molecular diagnostic solutions for culture-free infectious disease diagnostics, histology, cellular staining, osmolarity testing as well as monoclonal antibodies and recombinant proteins as raw materials for diagnostic assays.”
- Revenue$3.4BYoY +2.1%
- Net income−$8.6Mvs $113.1M year ago
- Revenue$874.0MYoY +1.6%
- Net income−$111.8MYoY −87.6%
CDNA CareDx, Inc
Sells it 85%, $322.9M a year“Our commercially available post-transplant testing services consist of AlloSure® Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap® Heart, a gene expression profiling solution for heart transplant patients, AlloSure® Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure® Lung, a dd-cfDNA solution for lung transplant patients.”
- Revenue$379.8MYoY +13.8%
- Net income−$21.4Mvs $52.5M year ago
- Revenue$139.4MYoY +39.3%
- Net income$19.3Mvs $1.7M year ago
DHR Danaher Corporation
Sells it 44%, $2.9B a quarter“Clinical diagnostics growth more than offset weaker respiratory testing.”
- Revenue$6.6BYoY +8.3%
- Net income$1.2BYoY +36.0%
MYGN Myriad Genetics
Sells it 100%, $824.5M a year“We develop and commercialize molecular tests that help patients and providers uncover genetic insights.”
- Revenue$824.5MYoY −1.6%
- Net income−$365.9MYoY −187.4%
- Revenue$202.7MYoY −1.5%
- Net income−$43.9MYoY −60.2%
TMO Thermo Fisher Scientific
Sells it 10%, $4.6B a year“Our Specialty Diagnostics segment offers a wide range of diagnostic test kits, reagents, culture media, instruments and associated products to serve customers in healthcare, clinical, pharmaceutical, industrial, and food safety laboratories.”
- Revenue$44.6BYoY +3.9%
- Net income$6.7BYoY +5.8%
- Revenue$12.1BYoY +9.1%
- Net income$1.7BYoY +6.5%
No companies have a recent 8-K matching these events.
No companies in the selected roles.